Literature DB >> 2885641

Faecal bile acids, dysplasia, and carcinoma in ulcerative colitis.

M J Hill, D M Melville, J E Lennard-Jones, K Neale, J K Ritchie.   

Abstract

A prospective study was undertaken between 1974 and 1985 of 102 patients with extensive ulcerative colitis (UC) of more than 10 years' duration. Faeces were collected for measurement of faecal bile acid concentrations (FBA), and the clinical outcome was recorded. The average faecal bile acid value among the 14 patients who showed carcinoma or definite dysplasia in the excised large bowel (9.86 [SE 0.81] mg/g FBA) was higher than in the 88 patients without dysplasia or carcinoma (7.51 [0.24] mg/g). These results lend support to the theory that bile acids are causally related to colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2885641     DOI: 10.1016/s0140-6736(87)90766-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  14 in total

Review 1.  Primary sclerosing cholangitis: updates in diagnosis and therapy.

Authors:  Piero Portincasa; Michele Vacca; Antonio Moschetta; Michele Petruzzelli; Giuseppe Palasciano; Karel J van Erpecum; Gerard P van Berge-Henegouwen
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

2.  Bile acid receptors and large bowel cancer.

Authors:  C L Berry
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

Review 3.  Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.

Authors:  A Boudewijn de Vries; Marcel Janse; Hans Blokzijl; Rinse K Weersma
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

Review 4.  Update on inflammatory bowel disease in patients with primary sclerosing cholangitis.

Authors:  Christos Tsaitas; Anysia Semertzidou; Emmanouil Sinakos
Journal:  World J Hepatol       Date:  2014-04-27

Review 5.  High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.

Authors:  Timothy Smith; Alex S Befeler
Journal:  Curr Gastroenterol Rep       Date:  2007-03

Review 6.  Vaccinia virus vectors: new strategies for producing recombinant vaccines.

Authors:  D E Hruby
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

7.  Intestinal FXR Activation via Transgenic Chimera or Chemical Agonism Prevents Colitis-Associated and Genetically-Induced Colon Cancer.

Authors:  Marica Cariello; Roberta Zerlotin; Emanuela Pasculli; Elena Piccinin; Claudia Peres; Emanuele Porru; Aldo Roda; Raffaella Maria Gadaleta; Antonio Moschetta
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

8.  Faecal bile acid excretion in children with inflammatory bowel disease.

Authors:  J Ejderhamn; J J Rafter; B Strandvik
Journal:  Gut       Date:  1991-11       Impact factor: 23.059

Review 9.  Chemoprevention of colorectal cancer in ulcerative colitis.

Authors:  Victoria J Croog; Thomas A Ullman; Steven H Itzkowitz
Journal:  Int J Colorectal Dis       Date:  2003-02-06       Impact factor: 2.571

Review 10.  Metabolic Reprogramming of Colorectal Cancer Cells and the Microenvironment: Implication for Therapy.

Authors:  Miljana Nenkov; Yunxia Ma; Nikolaus Gaßler; Yuan Chen
Journal:  Int J Mol Sci       Date:  2021-06-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.